| BackgroundChronic Renal Failure (CRF), a common disease, is a clinical syndrome of a variety of kidney diseases which lead to progressive irreversible kidney function decline until a loss of function through a series of symptom and metabolic disorders. Chronic renal failure is critical and with high mortality.The purpose of Western non-dialysis treatments for chronic renal failure is to relieve symptoms and delay progression. The main measures include slowing the progress of CRF reversible factors; treating of primary diseases such as hypertension and diabetic nephropathy; resisting of infections; maintaining a balance of water and electrolyte; delivering high quality and low protein diets, plus essential amino acids or keto acids; applying angiotensin converting enzyme inhibitor enzyme to reduce proteinuria and protect kidney function; regulating lipid metabolism; and improving the local presence of a glomerular hypercoagulable state.The Chinese medicine treatment for chronic renal failure in a single herb compound or combination therapy, utilizing multi-link, multi-level, multi-channel integrated measures to ease symptoms of chronic renal failure and protect renal function, thereby delaying progression.Years of clinical experience have shown that the treatment of chronic renal failure with a comprehensive application of Chinese and western medicines, especially after interventional treatment with Chinese medicine, alleviates symptoms of chronic renal failure, protects residual renal function and delays renal function decline as soon as early and mid-term progress. The comprehensive combination theraby delays dialysis and renal transplantation, resulting in improved quality of life for patients with CRF.Evidence supports that the Chinese medicine, Sanqi (radix astragali seu hedysari and Radix notoginseng)Oral Liquid, which has the effect of supplementing Qi and activating blood circulation, improves symptoms of chronic renal failure, delays the progression of chronic renal failure and protects renal function.In this study, cell adhesion factors, inflammatory factors, apoptosis and T cell subsets were observed. The multi-angle, multi-target effects of Sanqi Oral Liquid,a Chinese medicine, were observed after interventional treatment of renal function with Sanqi Oral Liquid.PurposeClinical changes were observed in Chronic renal failure patients using the Sanqi oral liquid. Experimental study of Chinese medicine Sanqi Oral Liquid was based on previous studies utilizing chronic renal failure rats in a 5/6 rephrectomy pathology model to ascertain the protective effect on kidney morphology and function to simulate chronic renal failure in patients.Using molecular biology, apoptosis, and lymphocyte levels, the effectiveness of Sanqi Chinese medicines Oral Liquid supplementing Qi and activating blood circulation in delaying the progress of CRF mechanism was studied.MethodsClinical Trials:95 patients were randomly divided into three groups:Sanqi groups, thirty-four pat ients received Sanqi Oral Liquid; Thirty patients were placed in the Niaoduqing group; Thirty-one patients received Sanqi Oral Liquid +Niaoduqing.Patients were separated into the treatment groups and control groups by visits, randomly. After 12 weeks, symptom scores, hemobl obin levels, hematorits, platelet counts, serum albumin, urea, creatine and potassium levels, as well as plateletαgranule membrane prote in changes were evaluated.Exper imental studies:78 SPF male SD rats, using the random number generated package PEMS 3.1 subjects were divided into 6 groups:control group-13, model control group-13, Sanqi Oral Liquid high-dose group (TMH) group-13, Sanqi Oral medium dose group (TMM) group-13, Sanqi Oral Liquid low-dose group (TML) group-13, including coated al dehyde oxystarch group-13. Rats in 5/6 nephrectomy model of chronic renal failure received Sanqi Oral Liquid interventional treatment. Then,12 weeks later the rats were observed in the general situation,their kidney function, hematocrit, platelet count and plateletαgranule membrane protein changes were registered. Pathologica! changes in glomerular state were studied under light microscope. Apoptosis analysis was conducted. TNF-α,TGFβ1,PGDFBB, and CD4, CD8 and CD68 changes were observed.ResultsClinical Trials:For the Sanqi Oral Liquid groups-a total efficiency of 82.4%; Sanq i Oral Liquid+Niaoduqing group-total efficiency of 96.8%. Compared to the Niaoduqing group, the differences were statistically significant (P<0.05). The Sanqi Oral Liquid group demonstrated significantly higher hematocrits and serum albumin and lower blood urea after treatment, compared to the Niaoduqing group (P<0.05). For the Sanqi Oral Liquid group before and after therapy, platelet a granule membrane protein (PS) decreased and the difference was statistically significant (P<0.05).Experimental Studies:In the Sanqi Oral Liquid group, the blood urea and serum creatinine decrease after treatment was statistically significant (P<0.05). The Sanqi Oral Liquid middle-dose (TMM) and low-dose (TML) PS group had a statistically significant low expression after treatment (P<0.05). In residual glomerular morphology, the Sanqi Oral Liquid treatment groups significantly reduced the increased glomerular area, tubularinjury was mild.Also in the coated aldehyde oxystarch group the difference was significance (P<0.05). In cytokine research, the Sanqi Oral Liquid treatment group, regardless of high, medium or low dosage decreased the expression level of TGFβ1, compared with the coated aldehyde oxystarch group, the difference was significant (P<0.05).Sanqi Oral Liquid in the middle dose group significantly reduced the increased in apoptosis,compared with the coated aldehyde oxystarch group, the difference was statistically significant (P<0.05).Sanqi Oral Liquid in the middle and low dose group significantly raised CD4 levels,CD4/CD8 ratio also significantly increased compared with the coated aldehyde oxystarch group, the difference was significant (P<0.05).Conclusions1. Sanqi Oral Liquid can improve clinical symptoms in patients with chronic renal failure points, improve clinical efficiency.2. Sanqi Oral Liquid can increase the level of serum albumin in chronic renal failure and improve nutritional status of patients. 3. Sanqi Oral Liquid can. decreases the blood expression lever of PS, improving the patient's blood stasis state, thereby protecting renal function.4.Sanqi Oral Liquid can reduced the 5/6 nephrectomized CRF rats Scr, increase the hematocr its and improve the body statue, thereby delaying the progress of renal function decline.5. Sanqi Oral Liquid can improve the 5/6 nephrectomy rats'renal pathological changes and provide residual renal protective effects.6. Sanqi Oral Liquid can inhibit TNF-α,PGDFBB and TGFβ1 expression to renal hypertrophy,glomerular hyperfiltration state, etc.at different levels of mitigation, in order to achieve protection of renal function.7.Sanqi Oral Liquid may significantly inhibit renal parenchymal cell apoptosis involved in the progression of renal disease and inhibit chronic renal sclerosis in 5/6 nephrectomy CRF rats.8.Sanqi Oral Liquid's protective effects on renal function may be related to adjustment of the ratio of CD4 and CD8 disorders, reducing adjustment disorders and immune abnormalities, resulting in a reduction of a variety of immune impairments and slowing the progress of CRF. |
PDF Full Text Request